Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

Not Applicable

• Conditions: -E119 Non-insulin-dependent diabetes mellitus, without complications; Non-insulin-dependent diabetes mellitus, without complications; E119

• Registration Number: PER-097-03
• Lead Sponsor: OVARTIS PHARMACEUTICALS CORPORATION,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2004-02-13
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Written informed consent to participate in the extension; ability to meet all the requirements of the study.

Exclusion Criteria

Premature discontinuation of the core phase of the study.
Concomitant medical conditions that interfere with the interpretation of the study results.
According to the definition of the core phase protocol; lack of compliance with the core phase of the protocol: patients that may be unreliable, and patients that the researcher considers unfit for study

Study & Design

• Study Type: Interventional
• Study Design: Not specified